CT-868

DRUG3 trials

Sponsors

Carmot Therapeutics, Inc.

Conditions

ObeseObesityOverweightType 1 DiabetesType 1 Diabetes MellitusType 2 Diabetes Mellitus

Phase 1

A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes

CompletedNCT05794581

Carmot Therapeutics, Inc.Type 1 Diabetes

Start: 2023-03-21End: 2024-04-06Updated: 2024-12-27

Phase 2

A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus

CompletedNCT05110846

Carmot Therapeutics, Inc.Obesity, Overweight, Type 2 Diabetes Mellitus

Start: 2022-02-22End: 2023-02-28Updated: 2026-02-05

A Study of CT-868 in Type 1 Diabetes Mellitus

CompletedNCT06062069

Carmot Therapeutics, Inc.Obese, Overweight, Type 1 Diabetes Mellitus

Start: 2023-10-19End: 2025-07-09Updated: 2025-07-17